Dr Frederic Delebecque – Director, Pre-Clinical Oncology
Frederic has a PhD in Virology from the University Pierre and Marie Curie in Paris, France, achieved at the Pasteur Institute. Following his PhD, he performed his postdoctoral training at the Pasteur Institute and at the prestigious University of California, Berkeley. He also has a degree in chemical engineering from the National Engineer School of Chemistry in Montpellier, France. In addition to his academic training, Frederic has extensive experience in Research and Development and Quality Assurance at leading pharmaceutical and biotech companies, including pre-clinical, clinical and medical research spanning several disease areas.
In 2009, Frederic joined Novartis Pharma AG in Basel, Switzerland as a Principal Scientist in the Laboratory of Cell line and Adventitious agents Analytics. He was involved in multiple cross-functional projects within Regulatory Chemistry, Manufacturing and Controls and oversaw the adventitious agents testing of production cell banks for biologicals generating regulatory documents for submission to health authorities (FDA, Swissmedic and EMA).
In 2011, Frederic moved to Australia and joined Calimmune, a clinical-stage multinational biotech company, as a Senior Scientist to supervise their pre-clinical work. After approval to conduct a Phase I/II clinical trial in the USA to test a unique stem-cell based gene therapy against HIV, Frederic moved to a Quality Assurance Director position in 2013. In this role, he was responsible for all Quality Assurance, including the development, implementation and maintenance of the Quality Management System globally across Australia and the USA.
Frederic joined Noxopharm in 2017 as the Director of Pre-clinical Oncology.